Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 109

Sort by

Sort Order Select

Journal Articles

Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degrader, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study

Blood (2019) 134 (Supplement_1): 232.

https://doi.org/10.1182/blood-2019-123966

Published: 2019

Journal Articles

A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Paul M. Barr, MD, Brian T. Hill, MD, Shuo Ma, MD PhD, Andrea M Baran, MS, Andrew Bui, Philip J Meacham, MS, Ashley Morrison, Jane L. Liesveld, MD, Deborah A Mulford, MD, Peter Sportelli, BS, Hari P Miskin, MSc, Michael S Weiss, Jonathan W. Friedberg, MD, Clive S Zent, MD

Blood (2019) 134 (Supplement_1): 360.

https://doi.org/10.1182/blood-2019-123404

Published: 2019

Journal Articles

Prevention and Management of Tumor Lysis Syndrome in Patients with CLL and Coexisting Conditions Treated with Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Results from the Randomized CLL14 Trial

Othman Al-Sawaf, MD, Anna-Maria Fink, MD, Sandra Robrecht, PhD, Arijit Sinha, PhD, Maneesh Tandon, MD, Barbara F. Eichhorst, MD, Kirsten Fischer, MD, Michael Hallek, MD

Blood (2019) 134 (Supplement_1): 4315.

https://doi.org/10.1182/blood-2019-126570

Published: 2019

Journal Articles

A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed/Refractory Acute Lymphoblastic Leukemia

Nitin Jain, MD, Kristen E. Stevenson, MS, Eric S. Winer, MD, Jacqueline S Garcia, MD, Richard M. Stone, MD, Elias Jabbour, MD, Farhad Ravandi, MD, Jeremy M. Stewart, BA, Dean R Legg, BA, Hagop M. Kantarjian, MD, Donna S Neuberg, ScD, Anthony G. Letai, MD PhD, Marina Y Konopleva, MD PhD, Daniel J. DeAngelo, MD

Blood (2019) 134 (Supplement_1): 3867.

https://doi.org/10.1182/blood-2019-129988

Published: 2019

Journal Articles

Efficacy of Methoxsalen Sterile Solution in Conjunction with the Therakos ® Cellex ® Photopheresis System in Pediatric Patients with Steroid-Refractory Acute GvHD: Interim Analysis

Carrie Kitko, MD, Stefania Gaspari, MD, Henri Boodée

Blood (2019) 134 (Supplement_1): 4524.

https://doi.org/10.1182/blood-2019-124061

Published: 2019

Journal Articles

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

Shinya Rai, MD PhD, Koji Kato, MD PhD, Junji Suzumiya, MD PhD, Koji Izutsu, MD PhD, Momoko Nishikori, MD PhD, Hirohiko Shibayama, MD PhD, Yoshinobu Maeda, MD PhD, Kenichi Yoshimura, PhD, Ukihide Tateishi, MD PhD, Toshihiro Miyamoto, MD PhD, Jun Ishikawa, MD PhD, Tsutomu Takahashi, MD PhD, Takahiro Yamauchi, MD PhD, Koichi Akashi, MD PhD, Yuzuru Kanakura, MD PhD

Blood (2019) 134 (Supplement_1): 5245.

https://doi.org/10.1182/blood-2019-126455

Published: 2019

Journal Articles

Original Versus Generic Lenalidomide in Patients with Relapsed Multipl Myeloma: Comprasion of Effectivity and Adverse Events

Zahit Bolaman, Sehmus Ertop, Atakan Turgutkaya, Selim Cem, Ayse Hilal Eroglu Kucukerdiler, Birsen Sahip, Irfan Yavasoglu, MD

Blood (2019) 134 (Supplement_1): 5594.

https://doi.org/10.1182/blood-2019-131093

Published: 2019

Journal Articles

A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy

Sudipto Mukherjee, MD PhD MPH, Hong Li, Brian P. Hobbs, PhD, Aaron T. Gerds, MD MS, Anjali S. Advani, MD, Hetty E. Carraway, MD MBA, Aziz Nazha, MD, Samjhana Bogati, RN, Eric Parsons, RN, Benjamin Pannell, Matt Kalaycio, MD, Yogenthiran Saunthararajah, MD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS

Blood (2019) 134 (Supplement_1): 2595.

https://doi.org/10.1182/blood-2019-132178

Published: 2019

Journal Articles

Efficacy of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: An Interim Analysis of a Phase 2 Study (the DARE Study)

Eftathios Kastritis, Evangelos Terpos, MD PhD, Argiris Symeonidis, MD PhD, Sosana Delimpasi, MD, Michele Cavo, Elena Zamagni, MD, Eirini Katodritou, MD, Barbara Gamberi, MD, Marie-Christine Kyrtsonis, MD PhD, Maria Gavriatopoulou, MD, Maria Roussou, MD, Despina Fotiou, MD, Evdoxia Hatjiharissi, Nikolaos Kanellias, MD, Magdalini Migkou, MD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1881.

https://doi.org/10.1182/blood-2019-124630

Published: 2019

Journal Articles

A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL

Jennifer L. Crombie, MD, Svitlana Tyekucheva, PhD, Alexandra Savell, BS, Karen Francoeur, RN, Mark Choiniere, BA, Josie Montegaard, NP, Jacob D. Soumerai, MD, Jon E. Arnason, MD, David C. Fisher, MD, Jennifer R. Brown, MD PhD, Matthew S. Davids, MD

Blood (2019) 134 (Supplement_1): 1763.

https://doi.org/10.1182/blood-2019-127343

Published: 2019

Journal Articles

Consolidation with Carfilzomib, Lenalidomide and Dexamethasone (KRd) Following ASCT Results in High Rates of Minimal Residual Disease Negativity and Improves Bone Metabolism, in the Absence of Bisphosphonates, Among Newly Diagnosed Patients with Multiple Myeloma

Maria Gavriatopoulou, MD, Evangelos Terpos, MD PhD, Ioannis Ntanasis-Stathopoulos, MD, Panagiotis Malandrakis, MD, Evangelos Eleutherakis-Papaiakovou, MD, Athanasios Papatheodorou, PhD, Nikolaos Kanellias, MD, Magdalini Migkou, MD, Despina Fotiou, MD, Ioanna Dialoupi, MD, Maria Roussou, MD, Nikoletta-Aikaterini Kokkali, Eftathios Kastritis, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 3118.

https://doi.org/10.1182/blood-2019-123916

Published: 2019

Journal Articles

Asian Subgroup Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study

Chang-Ki Min, MD PhD, Sung-Soo Yoon, MD PhD, Wee Joo Chng, MB ChB, PhD FRCP(UK), FRCPath, FAMS, Shang-Yi Huang, MD, PhD, Cheng-Shyong Chang, MD, Raymond Siu Ming Wong, Kazuyuki Shimizu, MD PhD, Nan Gao, Anthony Glennane, MD, Xuesong Guan

Blood (2018) 132 (Supplement 1): 3251.

https://doi.org/10.1182/blood-2018-99-113132

Published: 2018

Journal Articles

Durable Remission Achieved from Bcma-Directed CAR-T Therapy Against Relapsed or Refractory Multiple Myeloma

Yarong Liu, PhD, Zhi Chen, MD, Hongliang Fang, PhD, Runhong Wei, MD, Kang Yu, MD, Songfu Jiang, PhD, Weijun Fu, MDPhD, Hua Jiang, MD, Juan Du, PhD MD, Feng He, Ronglin Xie, Jing Chen, Baofeng Wei, Jin Tao, Pin Wang

Blood (2018) 132 (Supplement 1): 956.

https://doi.org/10.1182/blood-2018-99-112786

Published: 2018

Journal Articles

Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT 3 Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort

Jordi Esteve, MD PhD, Rik Schots, Teresa Bernal Del Castillo, MD PhD, Je-Hwan Lee, MD PhD, Eunice S. Wang, MD, Shira Dinner, MD, Mark D. Minden, MD PhD, Olga Salamero, MD, Jorge Sierra, MD, Goichi Yoshimoto, MD PhD, Kamel Laribi, MD, Janusz Halka, MD, Pau Montesinos, MD PhD, Shufang Liu, Elizabeth Shima Rich, MD PhD, Erkut Bahceci, MD

Blood (2018) 132 (Supplement 1): 2736.

https://doi.org/10.1182/blood-2018-99-110976

Published: 2018

Journal Articles

First-in-Human Mitochondrial Augmentation of Hematopoietic Stem Cells in Pearson Syndrome

Elad Jacoby, MD, Moriya Blumkin, PhD, Yair Anikster, MD PhD, Nira Varda-Bloom, PhD, Julia Pansheen, Omer Bar Yoseph, MD PhD, Noah Gruber, MD, Einat Lahav, MD, Michal J Besser, PhD, Jacob Schachter, MD, Noa Sher, PhD, Natalie Yivgi Ohana, PhD, Amos Toren, MD PhD

Blood (2018) 132 (Supplement 1): 1024.

https://doi.org/10.1182/blood-2018-99-113773

Published: 2018

Journal Articles

Evidence Based Recommendations for Supportive Care in Multiple Myeloma

Anum Qureshi, Muhammad Junaid Tariq, MD, Zunairah Shah, MBBS, Muhammad Abu Zar, MD, Shehroz Aslam, MD, Abdul Rafae, MD, Mustafa Nadeem Malik, MD, Ahmad Kamal, MD, Jemin Aby Jose, MD, Insija Ilyas Selene, MBBS, Madeeha Shafqat, Faiza Jamil, MD, Seren Durer, MD, Ceren Durer, MD, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 1952.

https://doi.org/10.1182/blood-2018-99-110748

Published: 2018

Journal Articles

Indoximod Combined with Standard Induction Chemotherapy Is Well Tolerated and Induces a High Rate of Complete Remission with MRD-Negativity in Patients with Newly Diagnosed AML: Results from a Phase 1 Trial

Ashkan Emadi, MD PhD, Vu H. Duong, MD, Jeremy Pantin, MD, Mohammad Imran, MD, Rima Koka, MD PhD, Zeba Singh, MBBS, Edward A. Sausville, MD PhD, Jennie Y. Law, MD, Seung Tae Lee, MD PhD, Huidong Shi, PhD, Ravindra Kolhe, MD PhD, Maria R. Baer, MD, Michael R. Loken, PhD, Eugene P. Kennedy, MD, Charles Link, MD, David H. Munn, MD

Blood (2018) 132 (Supplement 1): 332.

https://doi.org/10.1182/blood-2018-99-117433

Published: 2018

Journal Articles

Phase II Study of Hyper-Cmad with Liposomal Vincristine (Marqibo) for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Koji Sasaki, MD, Elias J. Jabbour, MD, Maria Khouri, Deborah A Thomas, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MBBS, Gautam Borthakur, MD, Nicholas J Short, MD, Ghayas C. Issa, MD, Tapan Kadia, MD, Emily Jones, Rebecca Garris, Msc, Jorge E. Cortes, MD, Susan M. O'Brien, MD, Hagop M. Kantarjian, MD

Blood (2017) 130 (Supplement 1): 2554.

https://doi.org/10.1182/blood.V130.Suppl_1.2554.2554

Published: 2017

Journal Articles

More Intensive Fludarabine/Busulfan (Flu/Bu) Conditioning Regimens Result in Similar Outcomes without Adding Serious Toxicity When Compared to Fludarabine/Melphalan (Flu/Mel) in Patients Undergoing Allogeneic Hematopoietic Cell Transplant (Allo-HCT)

Jeremy Pappacena, PharmD, Valkal Bhatt, PharmD, BCOP, BCPS, Gunjan L. Shah, MD, Patrick Hilden, MS, Molly Maloy, MS, Larry W Buie, PharmD, BCOP, FASHP, Sergio A. Giralt, MD, Michael Scordo, MD

Blood (2017) 130 (Supplement 1): 1950.

https://doi.org/10.1182/blood.V130.Suppl_1.1950.1950

Published: 2017

Journal Articles

The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial

Mahesh Swaminathan, MD, Hagop M. Kantarjian, MD, Naval Daver, MD, Gautam Borthakur, MD, Maro Ohanian, DO, Tapan Kadia, MD, Courtney D. DiNardo, MDMSc, Nitin Jain, MD, Zeev Estrov, MD, Alessandra Ferrajoli, MD, Guillermo Garcia-Manero, MD, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD, Naveen Pemmaraju, MD, Elias J. Jabbour, MD, William G Wierda, MD PhD, Farhad Ravandi, MBBS, Maria Rhona Pinsoy, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 723.

https://doi.org/10.1182/blood.V130.Suppl_1.723.723

Published: 2017

NARROW

Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degrader, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study

A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Prevention and Management of Tumor Lysis Syndrome in Patients with CLL and Coexisting Conditions Treated with Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Results from the Randomized CLL14 Trial

A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed/Refractory Acute Lymphoblastic Leukemia

Efficacy of Methoxsalen Sterile Solution in Conjunction with the Therakos ® Cellex ® Photopheresis System in Pediatric Patients with Steroid-Refractory Acute GvHD: Interim Analysis

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

Original Versus Generic Lenalidomide in Patients with Relapsed Multipl Myeloma: Comprasion of Effectivity and Adverse Events

A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy

Efficacy of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: An Interim Analysis of a Phase 2 Study (the DARE Study)

A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL

Consolidation with Carfilzomib, Lenalidomide and Dexamethasone (KRd) Following ASCT Results in High Rates of Minimal Residual Disease Negativity and Improves Bone Metabolism, in the Absence of Bisphosphonates, Among Newly Diagnosed Patients with Multiple Myeloma

Asian Subgroup Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study

Durable Remission Achieved from Bcma-Directed CAR-T Therapy Against Relapsed or Refractory Multiple Myeloma

Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT 3 Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort

First-in-Human Mitochondrial Augmentation of Hematopoietic Stem Cells in Pearson Syndrome

Evidence Based Recommendations for Supportive Care in Multiple Myeloma

Indoximod Combined with Standard Induction Chemotherapy Is Well Tolerated and Induces a High Rate of Complete Remission with MRD-Negativity in Patients with Newly Diagnosed AML: Results from a Phase 1 Trial

Phase II Study of Hyper-Cmad with Liposomal Vincristine (Marqibo) for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

More Intensive Fludarabine/Busulfan (Flu/Bu) Conditioning Regimens Result in Similar Outcomes without Adding Serious Toxicity When Compared to Fludarabine/Melphalan (Flu/Mel) in Patients Undergoing Allogeneic Hematopoietic Cell Transplant (Allo-HCT)

The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only